Furiex Pharmaceuticals, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Receives Approval of Additional NESINA(R) Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited’s applications for two additional indications for “NESINA®” (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare.